Other than that, I don't see why would they want to run two similar trials for naive cirrhotic patients as TURQUOISE-2. Plus, if your reason were correct, there would be no reason for them not to separate GT1a/1b into different arms in TURQUOISE-2.
I'm not saying this was the case. It's pure speculation concerning the delay of TURQUOISE-1. Poor results in GT1A cirrhotics would be more of a headline risk since the data could be extrapolated from the actual combined TURQUOISE-2 trial.
Market Data 
Markets 
AI
